Short answer: On July 27, 2026, Johnson & Johnson announced a proposed $5.5 billion resolution of about 76,000 ovarian cancer talc claims. It takes effect only if claims representing at least 95% of the remaining cases participate. The federal MDL 2738 before Judge Michael A. Shipp in New Jersey still had 69,376 pending cases on November 2, 2026.
The deal followed a July 22, 2026 order directing plaintiffs to show why their remaining claims should not be dismissed for inability to prove that talc caused each person’s cancer (specific causation). J&J denies its talc causes cancer.
- Timing: the first payment of no more than $3 billion is due in 2027, with no further payment due before 2028.
- Scope: existing ovarian cancer claims only. Future claims and mesothelioma cases are not part of it.
- Participation so far: lead negotiators reportedly told the court that 313 law firms representing about 66,500 claimants, roughly 87.5%, had agreed to join, still short of 95%. J&J has not announced that the threshold is met.
- What to watch: whether J&J waives or relaxes the 95% condition, or the deal stalls.
See the full talcum powder lawsuit guide or request a free, confidential case review.
SourcesJ&J talc dealFox Business / Reuters, 27 Jul 2026Settlement terms summaryExpert InstituteJPML report2 Nov 2026Participation reportLawsuit Information Center, Nov 2026



